EcoDrugPlus

Protein Kinase D3

Ensembl ID : ENSGACG00000006980
Gene Symbol: PRKD3
1 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSGACG00000001974
Gene Symbol: PRKDC
1 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSGACG00000019688
Gene Symbol: PPP3CA
2 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSGACG00000004011
Gene Symbol: PTK2
2 Cross references
240 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSGACG00000010609
Gene Symbol: PTK2BB
1 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSGACG00000015575
Gene Symbol: PTPN11A
1 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSGACG00000007601
Gene Symbol: PTPRB
2 Cross references
201 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSGACG00000017788
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSGACG00000016347
Gene Symbol: P2RX3B
1 Cross references
200 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSGACG00000010259
Gene Symbol: P2RY1
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSGACG00000010226
Gene Symbol: P2RY12
1 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSGACG00000008233
Gene Symbol: P2RY2
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).